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Purpose:  To  investigate  possible  genetic  associations  of  matrix  metalloproteinase-1  (MMP1)  and  MMP3  gene
polymorphisms with exfoliation syndrome (XFS) with (XFS/+G) and without (XFS/-G) glaucoma in a cohort of Greek
patients.
Methods: A total of 182 unrelated Greek patients with XFS, including 92 patients with XFS/+G, and 214 unrelated age-
and gender-matched controls were enrolled in the study. MMP1 -1607 1G/2G (rs1799750) and MMP3 -1171 5A/6A
(rs3025058) polymorphisms were determined using standard PCR/restriction fragment length polymorphism methods.
Differences in allele and genotype distributions were analyzed using logistic regression.
Results: The distribution of genotypes and alleles in MMP1 and MMP3 polymorphisms was not significantly different
between cases with exfoliation syndrome, with or without glaucoma, and controls. However, the allele contrast for the
MMP1 variant showed a trend for a significant association with XFS/-G (Odds Ratio=1.47 [1.03–2.10]), since after
correction for multiple comparisons, this association was no longer statistically significant.
Conclusions: Our study provided some evidence of a possible role of the MMP1 variant in the development of exfoliation
syndrome in Greek patients.
Exfoliation  syndrome  (XFS)  is  an  age-related
generalized disorder of the extracellular matrix associated
with  excessive  synthesis  and  progressive  deposition  of  a
fibrillar material in the ocular tissues as well as in the skin and
connective  tissue  of  various  visceral  organs  [1].  It  is
characterized by small whitish deposits of fibrillar-granular
material  in  the  anterior  segment  of  the  eye.  Its  ocular
manifestations  involve  all  the  structures  of  the  anterior
segment as well as the conjunctiva and the orbital tissues [2].
An increased number of associations of XFS with specific
systemic disorders [1] has been reported.
Raised  intraocular  pressure  develops  in  a  significant
number of patients with exfoliation syndrome. Exfoliation
glaucoma (XFS/+G) is a common sight-threatening disease
that  develops  as  a  consequence  of  exfoliation  syndrome.
There are important differences in the clinical appearance,
course, and prognosis of exfoliative glaucoma versus primary
open-angle glaucoma. On clinical, biochemical, and cellular
levels,  XFS/+G  is  a  distinct  entity  with  an  intriguing
mechanism  of  development  and  numerous  systemic
manifestations that require further elucidation [3].
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Extracellular  matrix  turnover  is  mediated  by  matrix
metalloproteinases (MMPs), a large family of endopeptidases
with  variable  substrate  spectra  [4].  The  activity  of  these
enzymes  is  regulated  in  part  by  specific  endogenous
inhibitors,  the  tissue  inhibitors  of  metalloproteinases
(TIMPs).  Complex  changes  in  the  local  MMP–TIMP  are
possible  candidates  to  be  involved  in  the  abnormal
extracellular matrix metabolism characteristic of XFS and
XFS/+G. Increased biosynthesis of MMPs in eyes with XFS
has been reported, and this may serve to degrade the abnormal
fibrillar matrix components in the anterior segment tissues
[5]. However, the increased levels of MMPs do not seem to
be able to overcome the overproduction and accumulation of
exfoliative  material  [5].  Growing  evidence  indicates  that
spontaneous sequence variations in the promoters of MMPs
may influence critical steps in the binding of transcription
factors or overall transcriptional efficiency, which results in
differential expression of MMPs in different individuals [6].
An  insertion  (2G)/deletion  (1G)  polymorphism
(rs1799750)  of  MMP1  (OMIM  120353,  chr.11q22-q23)
within the promoter region at position -1607 bp influences the
transcription of this MMP1 gene; the 2G promoter processes
greater transcriptional activity than the 1G promoter [7,8].
There is also a single adenine insertion (6A) or deletion
(5A) polymorphism (rs3025058) at position -1171 bp of the
MMP3 (OMIM 185250, chr.11q23) promoter that influences
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2890MMP3 expression by changing the affinity of the repressor
binding site, with the 6A allele sequence having a stronger
recognition  for  the  repressor  binding  site.  This  leads  to
enhanced transcriptional levels of MMP3 in the presence of
the 5A allele [6,9]. In addition, both MMP1 and MMP3 are
known to be adjacently localized in chromosome 11q22.3, and
these two loci are in linkage disequilibrium and considered to
act in cooperation [10].
Our  study  was  designed  to  investigate  whether  the
insertion/deletion polymorphisms of the MMP1 and MMP3
promoters have any correlation with the development of XFS,
and XFS/+G in particular. To our knowledge, this is the first
study that has evaluated the association between MMP1 and
MMP3 polymorphisms and XFS and XFS/+G.
METHODS
Patients and control subjects: This association study included
182 patients with unilateral or bilateral XFS, 92 of which had
unilateral  or  bilateral  exfoliation  glaucoma  (XFS/+G),  90
without  glaucoma  (XFS/-G),  and  214  age-  and  gender-
matched control subjects. All subjects were recruited from the
Ophthalmologic Department of the University Hospital of
Larissa (a tertiary referral center in central Greece that covers
a population of almost one million inhabitants). The study was
approved  by  the  local  ethics  committee  and  carried  out
according to the Declaration of Helsinki. All subjects were of
Greek nationality from the same geographic region and gave
informed consent before entering the study. The age and sex
distribution of the patients and controls are shown in Table 1.
All subjects underwent detailed ophthalmic examination
by the same investigator (P.M.). Patients or controls with any
type  of  malignancy,  autoimmune  disease,  ocular  disease,
history  of  cardiovascular  disease,  neurologic  disease,
obstructive pulmonary disease, diabetes mellitus, hepatitis, or
allergies  were  not  included  in  the  study  because  these
conditions have been associated with abnormal expression of
MMPs or their inhibitors [11].
In a detailed ophthalmologic examination, the anterior
and  posterior  segments  of  all  cases  were  evaluated,  and
intraocular pressures (IOPs) were measured with Goldmann
applanation  tonometry,  manufactured  by  Haag-Streit
(Koeniz-Berne Switzerland). The corneal endothelium, iris,
iris margins, and the anterior lens surface were evaluated for
exfoliative material before and after dilation. To evaluate the
angle for exfoliative material and increased pigmentation,
gonioprisms were used.
Patients were classified as having unilateral or bilateral
XFS  by  the  presence  of  characteristic  fibrillar-exfoliate
material on the anterior lens capsule or pupillary margin and
by an open anterior chamber angle. Unilateral or bilateral
XFS/+G was manifested if patients had XFS as well as an IOP
greater than 22 mmHg in each eye, typical glaucomatous optic
nerve  changes  (notching,  thinner  neuroretinal  rim,  and
increased cup-to-disc ratio), and the presence of visual field
defects, as determined by a Humphrey visual field analyzer,
(full threshold program 24-2; Carl Zeiss Inc., Dublin, CA),
consistent with the glaucomatous cupping in at least one eye.
The mean IOP at diagnosis was 17±4 mmHg in the patients
with XFS and 35.0±13.0 mm Hg in the patients with XFS/+G.
Control subjects had no evidence of exfoliative material
at the anterior lens capsule or pupillary margin. In addition the
IOP in control subjects was less than 22 mm Hg; control
subjects had normal visual fields, an open anterior chamber
angle, no evidence of glaucomatous changes in the optic disc,
and no history of glaucoma or ocular hypertension in first-
degree relatives.
MMP1  and  MMP3  polymorphisms:  Genomic  DNA  was
extracted  from  peripheral  blood  leukocytes  using  a
commercially  available  DNA  extraction  kit  (Qiagen,
Valencia, CA), according to the manufacturer’s instructions.
Based on the sequences of MMP1 and MMP3 available from
GenBank and using Primer3 software, appropriate primers
were designed for MMP1 (1G/2G, -1607) and MMP3 (5A/6A,
-1171) polymorphisms (Table 2). Thermal cycling conditions
were as follows: 15 min at 95 oC, followed by 35 cycles of 30
s at 95 oC, 30 s at 56 oC (MMP1) or 30 s at 65 oC (MMP3), 30
s at 72 oC, and with a final extension at 72 oC for 5 min. PCR
products were digested for 16 h at 37 oC in a 24-μl reaction
containing 2 μl AluI and 2 μl ΤthIII restriction enzymes for
the  determination  of  MMP1  and  MMP3  genotypes,
respectively.  The  digested  products  were  subjected  to  gel
electrophoresis  and  were  visualized  by  ethidium  bromide
staining.  The  sizes  of  PCR  products  for  MMP1  (1G/2G,
-1607) and MMP3 (5A/6A, -1171) were 269 and 129 bp,
respectively.
Statistical analysis: The Hardy–Weinberg (H-W) equilibrium
[12]  was  assessed  by  means  of  an  exact  H-W  test,
implemented in the GENEPOP version 3.4 program. Power
TABLE 1. CLINICAL CHARACTERISTICS OF STUDY POPULATIONS.
Gender/Age XFS Total (n=182) XFS/+G (n=92) XFS/-G (n=90) Controls (n=214)
Female (%) 111 (60.9) 58 (63.1) 53 (58.9) 122 (57.0)
Age±SD (years) 72.0±7.1 71.3±7.7 72.9±6.1 71.8±7.8
In the table, XFS refers to exfoliation syndrome, XFS/+G refers to exfoliation syndrome with glaucoma, and XFS/-G refers to
exfoliation syndrome without glaucoma.
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Studies  (Center  for  Statistical  Genetics,  University  of
Michigan,  Ann  Arbor,  MI).  Continuous  variables  were
compared (XFS total, XFS/+G, or XFS/-G versus controls)
using  the  nonparametric  Mann–Whitney  U  test,  and
categorical  variables  were  compared  using  the  χ2  test.
Differences in allele and genotype distributions were analyzed
using  logistic  regression.  The  odds  ratio  (OR)  and  95%
confidence interval (CI) were used as a measure of strength
of association between polymorphisms and disease. In the
logistic regression, the disease status (patients versus controls)
was used as a dichotomous outcome, while allele or genotype
was  used  as  a  predictor.  We  additionally  controlled  for
potential confounders, such as age and gender. Later analyses
were carried out using SPSS ver. 12.0 (SPSS, Chicago, IL).
Control  for  multiple  comparisons  was  performed  using
Bonferronis correction for two polymorphisms. The level of
significance (p) was equal to 0.025 (0.05/2=0.025).
RESULTS
Patients and controls were in Hardy–Weinberg equilibrium
(p>0.05 for all groups). Differences in mean age and sex
distribution  between  all  patients  and  controls  were  not
significant (p>0.05). Distribution of genotypes and alleles are
shown  in  Table  3.  In  both  polymorphisms  (MMP1  and
MMP3), the genotype distribution of the XFS total group was
not significantly different from controls (p=0.19 and p=0.99).
Also,  the  genotype  distributions  of  XFS/+G  and  XFS/-G
groups  were  not  significantly  different  from  controls
(MMP1 p=0.10 and 0.70, respectively, and MMP3 p=0.94 and
0.48, respectively).
The  results  of  the  influence  of  genotypes  on  disease
susceptibility  based  on  carrier  status  of  risk  allele  and
considering the allele contrast and the dominant and recessive
models are shown in Table 4. The allele contrast for the
MMP1 variant showed a trend for a significant association for
XFS/-G  (1.47  [1.03–2.10];  p=0.04).  This  association  is
considered  nonsignificant  after  correction  for  multiple
comparisons  (level  of  significant  <0.025).  However,  the
dominant and recessive models showed that MMP1 was not
associated  with  XFS  total  (OR=1.51  [0.87–2.46]  and
OR=0.73 [0.46–1.13], respectively). The MMP3 variant was
not associated with XFS total for the allele contrast and the
dominant  and  recessive  models  (OR=0.90  [0.68–1.19];
OR=1.09  [0.68n–1.65];  and  OR=1.03  [0.66–1.54],
respectively). The subgroups XFS/+G and XFS/-G produced
similar results to the XFS total for both variants.
DISCUSSION
XFS is a complex disorder with both genetic and nongenetic
factors involved in its development and progression. Among
nongenetic factors, ultraviolet light, autoimmunity, slow virus
infection, and trauma have been suggested as contributing
factors to XFS [13].
TABLE 2. PRIMER SEQUENCES FOR MMP1 (1G/2G, -1607) AND MMP3 (5A/6A, -1171) POLYMORPHISMS.
Gene Polymorphism Forward primer (5’-3’) Reverse primer 5’-3’
MMP1 1G/2G (rs1799750) TGACTTTTAAAACATAGTCTATGTTCA TCTTGGATTGATTTGAGATAAGTCATAGC
MMP3 5A/6A (rs3025058) GGTTCTCCATTCCTTTGATGGGGGGAAAGA CTTCCTGGAATTCACATCACTGCCACCACT
TABLE 3. GENOTYPE AND ALLELE DISTRIBUTION FREQUENCIES OF THE MMP1 -1607 POLYMORPHISM AND THE MMP3 -1171
POLYMORPHISM.
Genotypes/
Alleles
XFS Total
(n=182) p-value
XFS/+G
(n=92) p-value
XFS/-G
(n=90) p-value
Controls
(n=214)
MMP-1
2G/2G (%) 24 (13.2)   11 (11.9)   13 (14.4)   39 (18.2)
2G/1G (%) 89 (48.9)   42 (45.7)   47 (52.3)   110 (51.4)
1G/1G (%) 69 (37.9) 0.19 39 (42.4) 0.10 30 (33.3) 0.70 65 (30.4)
1G (%) 227 (62.4)   120 (65.2)   107 (59.5)   240 (56.1)
2G (%) 137 (37.6) 0.07 64 (34.8) 0.04 73 (40.5) 0.44 188 (43.9)
MMP-3
6A/6A (%) 42 (23.1)   25 (27.2)   17 (18.9)   54 (25.2)
6A/5A (%) 87 (47.8)   42 (45.6)   45 (50.0)   101 (47.2)
5A/5A (%) 53 (29.1) 0.99 25 (27.2) 0.94 28 (31.1) 0.48 59 (27.6)
5A (%) 193 (53.0)   92 (50.0)   101 (56.1)   219 (51.2)
6A (%) 171 (47.0) 0.99 92 (50.0) 0.79 79 (43.9) 0.29 209 (48.8)
Genotype and allele distribution frequencies of the MMP1   -1607 polymorphism and the MMP3 -1171 polymorphism in the
exfoliation syndrome (XFS Total), exfoliation syndrome with glaucoma (XFS/+G), exfoliation glaucoma without glaucoma
(XFS/-G and control groups. The p-values for comparing each diseased group with the controls are also shown.
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2892Exfoliation syndrome is often clustered in families, so it
has been proposed that genetic factors play an important role
in its cause [14]. In an Icelandic twin study, five of eight
monozygotic twins with exfoliation were concordant for XFS
[15],  as  was  the  case  in  another  small  case  study  of
monozygotic twins [14]. Segregation analyses conducted on
the Finnish population clearly showed heredity to be a primary
contributor  to  XFS  susceptibility  [14],  and  recently  the
susceptible loci were proposed to be 18q12.1–21.33, 2q, 17p,
and 19q.9 [16].
In  addition,  genetic  association  studies  have  been
conducted  to  investigate  the  association  between  genetic
polymorphisms and XFS with or without glaucoma. Recent
studies  showed  that  lysil  oxidase-like  1  (LOX1)  gene
polymorphisms  are  highly  associated  with  exfoliation
phenotype [17–20]. Replication studies in other populations
have  confirmed  genetic  susceptibility  of  LOXL1
polymorphisms  to  XFS  [17,21,22],  demonstrating  that
LOXL1 is a major gene associated with XFS. Polymorphisms
in  glutathione  S-transferase  (GST)  genes
(GSTM1,GSTT1,GSTP1) [23] and the tumor necrosis factor-
α gene (TNFα) -308 G/A have also been tested in XFS [24,
25].
MMPs and their inhibitors are shown to play an important
role in the development of an abnormal extracellular matrix
characteristic of XFS/XFS/+G [2,26]. Increased biosynthesis
of  MMPs  has  been  found  in  XFS,  which  may  limit  the
progression of XFS by degrading the abnormal fibrillar matrix
components in the anterior segment tissues; however, it was
also  suggested  the  MMPs  may  have  a  role  in  promoting
exfoliation [5]. MMP1 (1G/2G, -1607) and MMP3 (5A/6A,
-1171)  functional  polymorphisms  have  been  studied  in
various diseases and in several populations [6]. They have
been  associated,  among  others,  with  increased  risk  for
colorectal  cancer  [10],  carotid  artery  disease  [27],  acute
myocardial  infarction  [28],  and  idiopathic  dilated
cardiomyopathy [29].
In the present study, we determined the genotypes of two
functional  polymorphisms,  MMP1  (1G/2G,  -1607)  and
MMP3 (5A/6A, -1171), in healthy individuals and in patients
with XFS and XFS/+G, and for the allele contrast we found a
trend for association only between the MMP1 variant and XFS
without glaucoma.
We should underscore that the sample size in our study
was small, and thus the power of detecting significant results
was  limited  (almost  20%).  However,  candidate-gene
association studies have the tendency to lack the power to
detect a statistically significant association. For example, in
order to achieve a power >80% to identify a modest genetic
effect (odds ratio 1.2) of a polymorphism present in 10% of
individuals, a sample size of 10,000 subjects or more would
be needed [30,31]. Therefore, the sample sizes required to
predict association have to be far beyond what is currently
available, and no single institution or entity alone would be
able to provide a reasonable number of patients. However, a
future meta-analysis of multiple studies clearly has a role in
offering an analysis with the potential for higher power [32].
Future collaborative studies may allow the pooling of data,
providing  more  power  to  detect  significant  associations.
Furthermore,  consortia  performing  gene-candidate  or
genome-wide association studies will be able to replicate the
validity of the present findings [33].
Nevertheless,  the  present  study  fulfills  the  minimum
requirements for the association study to be informative [32].
TABLE 4. INFLUENCE OF GENOTYPES ON DISEASE SUSCEPTIBILITY BASED ON CARRIER STATUS OF RISK ALLELE CONSIDERING DOMINANT OR RECESSIVE MODEL.
Model MMP-1 (-1607 1G/2G) MMP-3 (-1171 5A/6A)
Allele contrast 1G 2G OR (95%CI)* p 6A 5A OR (95%CI)*               p
Controls 240 188 Reference   209 219 Reference  
Patients-XFS/+G 120 64 1.47 (1.03-2.10) 0.04 92 92 0.95 (0.68-1.35) 0.79
Patients-XFS/-G 107 73 1.15 (0.81-1.64) 0.44 79 101 0.75 (0.53-1.06) 0.29
Patients-XFS total 227 137 1.30 (0.98-1.73) 0.07 171 193 0.90 (0.68-1.19) 0.99
Dominant model 1G/- -/- OR (95%CI)* p 5A/- -/- OR(95%CI)* p
Controls 175 39 Reference   160 54 Reference  
Patients-XFS/+G 81 11 1.61 (0.78-3.35) 0.18 67 25 0.89 (0.50-1.53) 0.68
Patients-XFS/-G 77 13 1.33 (0.68-2.65) 0.46 73 17 1.42 (0.74-2.61) 0.25
Patients-XFS total 158 24 1.51 (0.87-2.46) 0.20 140 42 1.09 (0.68-1.65) 0.91
Recessive model 1G/1G 2G/- OR (95%CI)*   p 5A/5A 6A/- OR (95%CI)*   p
Controls 65 149 Reference   59 155 Reference  
Patients-XFS/+G 39 53 0.62 (0.43-0.98) 0.05 25 67 1.04 (0.58-1.73) 0.93
Patients-XFS/-G 30 60 0.90 (0.50-1.48) 0.65 28 62 0.86 (0.49-1.38) 0.57
Patients-XFS total 69 113 0.73 (0.46-1.13) 0.13 53 129 1.03 (0.66-1.54) 0.97
The asterisk indicates that OR was adjusted for age and gender.
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2893These  include  population-based  matched  controls,  good
scientific  rationale,  presence  of  H–W  equilibrium  in
genotypes, and a similar ethnic background. In parallel, our
study has all the limitations that are applicable to genetic
association  studies  [34].  Because  our  hospital  is  the  only
tertiary institution covering a rural and urban region with
nearly 1 million inhabitants, patients included in this study are
population-based XFS patients. For this reason, more severe
patients are usually referred to our hospital, and we cannot
exclude  the  possibility  that  a  selection  bias  may  have
occurred.
In  summary,  our  study  provided  some  evidence  of  a
possible  significant  role  of  the  MMP1  variant  in  the
development  of  exfoliation  syndrome  in  Greek  patients.
However,  as  we  cannot  exclude  the  possibility  that  our
findings were due to random events or type 1 error, further
studies using large cohorts of patients are needed to explore
the possible genetic involvement of the above polymorphisms
in the exfoliation syndrome.
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